GENE EDITING SOLUTIONS

Delivering the Next Evolution of Healthcare

Recombinetics is a recognized leader in animal gene editing and associated applied technologies for biomedical research, regenerative medicine and animal agriculture.

We leverage our proprietary gene editing platform to commercialize and deploy technologies through four subsidiaries that pivotally impact human health and longevity and add value to farm animals.

FACING THE FACTS

113,000

people are currently on the U.S. transplant list—83% are waiting for a kidney

90%

of all clinical trials fail

1.5 BILLION

smallholders are raising unproductive animals

our work

Groundbreaking Technology for Life-Changing Solutions

Recombinetics has the most experienced and reliable animal gene-editing team on the planet developing solutions through four customer-facing subsidiaries focused on three key areas:

regenerative medicine

Developing Transplantable Cells, Tissues and Organs to Save Lives

We enable the most precise possible resolution to human illness through the ability to provide patients with tissue and organ transplantation created using their own cells.

Learn More

Addressing the Organ Shortage Crisis through Xenotransplantation

We’re transforming the lives of patients with organ failure by providing an abundant source of donor organs from genetically engineered pigs.

Learn More

preclinical research

Delivering Better Models to Understand Human Disease

We help preclinical researchers study disease pathology and evaluate the safety and efficacy of novel therapeutics through precise pig models of human diseases such as heart disease, neurodegenerative diseases, genetic/rare diseases, diabetes and cancer.

Learn More

precision breeding

Producing Healthier, Happier Animals and More Sustainable Farming

We use state-of-the-art breeding methods to precisely deliver traits that improve the health, welfare and sustainability of food animals to feed a hungry world while protecting the environment.

Learn More

notable news

Recombinetics Merges with Makana Therapeutics to Accelerate Transplantation

Makana Therapeutics has become Recombinetics Inc.’s newest subsidiary and is exclusively focused on addressing the organ shortage crisis. Recombinetics and Makana have expertise and strong, synergistic intellectual property positions in clinical organ transplantation, genetic engineering, reproductive technology, and xenotransplantation. The merger allows our scientists to focus on and commercialize a pipeline of transplantable cells, tissues, and organs for human patient use.

Your investment can help us change the world.

Reach out today for information on how you can make a difference.